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AD patients were not on anti-alzheimer’s medication both in
2005 and 2006. Closer scrutiny on these trends is required to
alleviate AD disease burden.
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OBJECTIVES: To assess treatment patterns and associated
patient characteristics among PD patients in a multi-center setting
in Spain, and generate estimates at country-level. METHODS:
NeuroMonitor is an annual study conducted among neurologists
in hospitals and private practices to collect chart data (disease/
patient characteristics & treatment patterns) on patients receiving
medications to treat neurologic conditions during the study
window/encounter. Current analysis of PD patients in Spain uti-
lized 2006 data from 102 neurologists & 1030 patient charts. A
multi-stage weighting method at physician/patient level was
employed to extrapolate data to Spain population. RESULTS:
Among patients receiving neurologic agents in 2006, over 85,000
patients were estimated to have PD (average age: 71 yrs; female:
40%; disease stages per H&Y scale, I: 13%, II: 37%, III: 34%, IV:
12%, V: 1%). Majority (87%) of PD-patients were diagnosed by
neurologists, and 42%, 21% & 37% of patients were diagnosed
within 1-yr, 1–2 yrs & >2-yrs respectively. Key comorbidities
included: Hypertension (53%), dyslipidemia (29%), diabetes
(26%), osteoarthritis (24%), depression (26%) & anxiety/
dementia (12% each). Majority (98%) of PD-patients rec-
eived anti-parkinson’s medications, with sparse use of antidepres-
sants (2%) and anticholinergics/antipsychotics/anti-alzheimers/
hypnotics-sedatives (1% each). Among those using anti-
parkinson’s medication, utilization patterns varied by disease
severity—levadopa-based: total-77%, mild-62%, moderate-
91%, severe-96%, cabergoline: total-15%, mild-12%, moderate-
16%, severe-20%, pramipexole: total-14%, mild-16%,
moderate-11%, severe-12%, ropinirol: total-11%, mild-
10%,moderate-11%, severe-18%, selegiline: total-9%,mild-9%,
moderate-8%, severe-9%, entacapone: total-7%, mild-3%,
moderate-8%, severe-22%, rasagiline: total-5%, mild-
6%, moderate-4%, severe-5%. CONCLUSION: Almost half of
PD patients were diagnosed within last 1-yr and majority had
moderate disability. In spite of prevalence of psychiatric comor-
bidities, only few patients were on appropriate concomitant medi-
cations. Levodopa-based PD regimen use was widely prevalent,
followed by dopamine-agonists; extent of use differed by disease
severity. Further research iswarranted to assess the impact of these
patterns on long-term outcomes.
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OBJECTIVES: Drug-related problems (DRPs) are very likely to
occur among patients with Parkinson’s disease (PD). With regard
to the complexity of PD’s long-term treatment regimen, there is
an increasing need for the systematic monitoring of drug thera-
pies in outpatient settings. The aim of this study was to evaluate
the advantages of a counselling guideline for the detection of
DRPs in Parkinson patients used in community pharmacies.
METHODS: The counselling guideline included standardised
questionnaires on the drug treatment and a checklist of common
DRPs induced by antiparkinsonian agents, part of which were
reported by patients in supervised internet forums. Thirty-two
pharmacies in Germany were recruited for the study. In accor-
dance with the guideline each pharmacy monitored PD patients
for eight months. A total of 112 patients were included to the
study and checked for potential or actual occurrences of DRPs.
The DRPs were then categorised using the Problem Intervention
Documentation (PI-Doc). Medication proﬁles and dose regimens
were adjusted in cooperation with the treating physician where
appropriate. RESULTS: In total, 331 DRPs were identiﬁed. Lack
of medication despite indication, especially for non-motor symp-
toms (26.6%), adverse drug reactions (12.4%), inappropriate
time of administration (10.0%), under-dosage (9.7%) and drug
interactions (9.4%) accounted for the highest percentage of
DRPs. Pharmacists’ use of the counselling guideline led to an
improvement of the drug regimen in more than half of the cases
(52.6%). In addition, four patients were identiﬁed who were
misdiagnosed with PD. CONCLUSION: The disease speciﬁc
counselling guideline supports the detection of DRPs and should
be part of routine assessment of patients with PD.
NEUROLOGICAL DISORDERS—Methods and Concepts
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OBJECTIVES: To demonstrate the feasibility of a person-
level net beneﬁts (NB) approach to estimating marginal cost-
effectiveness, with an application to disease-modifying drugs
(DMDs) in multiple sclerosis (MS). The NB approach to estimat-
ing cost-effectiveness has been shown to overcome statistical
issues associated with the conventional incremental cost-
effectiveness ratio. A person-level NB approach can be used to
estimate marginal cost-effectiveness and conﬁdence intervals.
METHODS: The NB variable value for each data point was
calculated as MS-speciﬁc or generic health status (HS), weighted
by a threshold willingness-to-pay per QALY gain (l), less direct
costs (NB = HS.l - (cDMD + cHC)). A ﬁxed effects model
regressed NB against explanatory variables, including years since
MS onset and DMD treatment years. b-coefﬁcients for explana-
tory variables represent their marginal contributions to overall
NB. For DMD treatment years, the l at which b = 0 represents
the threshold willingness-to-pay per QALY, where marginal mon-
etized health outcomes equal marginal (net) costs. The study
population includes all 1995–2004 residents of Nova Scotia,
Canada, with relapsing-onset deﬁnite MS treated with DMDs
under a universal insurance program begun in 1998 and deliv-
ered by the Dalhousie MS Research Unit clinic. Data included
repeat-visit measures of MS-speciﬁc disability (Expanded Dis-
ability Status Scale), generic health-related-quality-of-life (Health
Utilities Index Mark III), DMD costs (cDMD) and annual direct
health care costs (cHC) for physician, hospital and pharmacare
utilization. RESULTS: b-coefﬁcients estimated with the NB
model moved in the expected direction as l was varied. The
b-coefﬁcient on DMD treatment years was strongly negative at
relatively low willingness-to-pay thresholds and increased with l.
CONCLUSION: The person-level NB approach is feasible. It
generates marginal cost-effectiveness estimates that have statisti-
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